12th International Conference on the Molecular Biology and Pathogenesis of Clostridia (Clostpath 12)
第十二届梭状芽胞杆菌分子生物学和发病机制国际会议 (Clostridia 12)
基本信息
- 批准号:10318438
- 负责人:
- 金额:$ 1.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-12 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:Alberta provinceCanadaClinicalCollaborationsCommunitiesDetectionDevelopmentDiagnosisDiseaseEventFemaleFosteringFundingFutureGenderGene Expression RegulationGeographyHealthHeartHumanIndividualInternationalLivestockMinority GroupsMolecular BiologyOralOrganismPathogenesisPathogenicityPathologistPersonsPreventionReproduction sporesResearchResearch PersonnelRoleScientistStructureStudentsTimeTrainingTravelUnderrepresented MinorityVirulenceVirulence FactorsWorkcareercareer developmentdesigndigitaldiversity and inclusioninnovationmeetingsmicrobiomenew technologynext generationpathogenpostersprogramsracial diversitysocialsymposiumtransmission process
项目摘要
SUMMARY
The International Conference on the Molecular Biology and Pathogenesis of the Clostridia (Clostpath) has been
the leading venue to bring together scientists, clinicians, and pathologists at the forefront of research on the
molecular biology of clostridia and their role in health and disease. In keeping with this tradition, Clostpath12 will
cover all fundamental and translational aspects of clostridial-dependent pathogenesis. Topics will include
virulence gene regulation, virulence factor structure and mechanism, host-pathogen-microbiome interactions,
spore dynamics and transmission, the development of new technologies to study clostridial organisms, as well
as innovations designed for the detection, diagnosis, treatment and prevention of clostridial-caused diseases.
The meeting will take place September 13-16, 2021 in Banff, Alberta, which is located in the heart of the
Canadian Rockies.
The programming for Clostpath12 is deliberate in its focus on diversity and inclusion as well as providing
opportunities to young scientists. At Clostpath conferences, there are traditionally 9 sessions, with 12-20 invited
speakers – all plenary (no parallel sessions). Approximately 25 additional oral presentations will be selected from
submitted abstracts. The Organizing Committee, the International Steering Committee, and the list of invited
speakers reflect the full geographic, scientific, and ethnic/gender/racial diversity of the Clostpath community.
There will be ~150 posters presented, divided over two poster sessions. During the plenary presentations, there
will also be flash talks for selected poster abstracts. To foster networking interactions, there is a social program
that includes a welcome reception/working dinner on the first day of the conference, a conference dinner/party
on the final evening, and optional excursions. In addition, a young scientist committee is developing trainee-
specific content and activities to be integrated into the program.
The objectives for the 12th Conference will be (i) to continue presenting the highest-quality, recent research on
pathogenic clostridia in a forum that facilitates information exchange and future collaborations and (ii) to train
and inspire young clostridial researchers who will be the next generation of leaders in the field. These objectives
will be realized through two specific aims: Aim 1: Invite, support, and encourage the participation of young
investigators and underrepresented scientists. Aim 2: Provide a setting that encourages collegial exchange of
scientific ideas and sharing of the most current discoveries in the field.
总结
梭菌分子生物学和发病机制国际会议(Clostpath)已于
领先的场地,汇集科学家,临床医生,病理学家在研究的前沿,
梭菌的分子生物学及其在健康和疾病中的作用。为了保持这一传统,Clostpath 12将
涵盖梭菌依赖性发病机制的所有基本和转化方面。议题将包括
毒力基因调控,毒力因子结构和机制,宿主-病原体-微生物组相互作用,
孢子动力学和传播,研究梭菌生物的新技术的发展,以及
作为用于检测、诊断、治疗和预防梭菌引起的疾病的创新。
会议将于2021年9月13日至16日在阿尔伯塔的班夫举行,班夫位于阿尔伯塔省的中心地带。
加拿大落基山脉。
Clostpath 12的编程刻意关注多样性和包容性,并提供
为年轻科学家提供机会。在Clostpath会议上,传统上有9个会议,邀请12-20人
发言人-全体会议(无平行会议)。将从以下项目中选出大约25个额外的口头报告:
提交摘要。组委会、国际指导委员会和受邀者名单
演讲者反映了Clostpath社区的地理,科学和种族/性别/种族多样性。
将有~150海报提出,分为两个海报会议。在全体会议上,
也将为选定的海报摘要进行快闪演讲。为了促进网络互动,
包括会议第一天的欢迎招待会/工作晚餐,会议晚餐/派对
在最后一个晚上,和可选的短途旅行。此外,一个青年科学家委员会正在培养实习生-
具体内容和活动纳入方案。
第12届会议的目标将是:(一)继续提出最高质量的最新研究,
致病性梭菌在一个论坛,促进信息交流和未来的合作和(ii)培训
并激励年轻的梭菌研究人员,他们将成为该领域的下一代领导者。这些目标
将通过两个具体目标来实现:目标1:邀请、支持和鼓励年轻人的参与
调查人员和代表性不足的科学家。目标2:提供一个环境,鼓励大学生交流
科学思想和分享该领域的最新发现。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dana Borden Lacy其他文献
Dana Borden Lacy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dana Borden Lacy', 18)}}的其他基金
Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines
艰难梭菌疫苗的范德比尔特抗体和抗原发现
- 批准号:
10625686 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Project 1: Mucosal toxin subunit immunization as a strategy for C. difficile vaccine development
项目 1:粘膜毒素亚基免疫作为艰难梭菌疫苗开发的策略
- 批准号:
10625692 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
The role of toxins in Clostridium difficile infection pathogenesis
毒素在艰难梭菌感染发病机制中的作用
- 批准号:
10412917 - 财政年份:2015
- 资助金额:
$ 1.1万 - 项目类别:
Pre-clinical evaluation of Clostridium difficile toxin inhibitors
艰难梭菌毒素抑制剂的临床前评价
- 批准号:
9487905 - 财政年份:2015
- 资助金额:
$ 1.1万 - 项目类别:
The role of toxins in Clostridium difficile infection pathogenesis
毒素在艰难梭菌感染发病机制中的作用
- 批准号:
9889242 - 财政年份:2015
- 资助金额:
$ 1.1万 - 项目类别:
The role of toxins in Clostridium difficile infection pathogenesis
毒素在艰难梭菌感染发病机制中的作用
- 批准号:
10516088 - 财政年份:2015
- 资助金额:
$ 1.1万 - 项目类别:
Structural mechanisms of Clostridium difficile pathogenesis
艰难梭菌发病机制的结构机制
- 批准号:
9212765 - 财政年份:2011
- 资助金额:
$ 1.1万 - 项目类别:
Structural Mechanisms of Clostridioides difficile pathogenesis
艰难梭菌发病机制的结构机制
- 批准号:
10620653 - 财政年份:2011
- 资助金额:
$ 1.1万 - 项目类别:
Structural mechanisms of Clostridium difficile pathogenesis
艰难梭菌发病机制的结构机制
- 批准号:
9916698 - 财政年份:2011
- 资助金额:
$ 1.1万 - 项目类别:
相似海外基金
Toward Effective Policy and Clinical Care in the Context of Track 2 MAID in Canada
在加拿大第二轨道 MAID 的背景下迈向有效的政策和临床护理
- 批准号:
488023 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Operating Grants
REACHing underserved and undiagnosed populations living with STBBIs to test and link them to care: Implementing innovative clinical trials (iCTs) designs to "test and treat" and bring new rapid point-of-care and self-tests to market in Canada
覆盖服务不足和未确诊的 STBBI 患者,对他们进行测试并将其与护理联系起来:实施创新的临床试验 (iCT) 设计来“测试和治疗”,并将新的快速护理点和自我测试推向加拿大市场
- 批准号:
481601 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Operating Grants
Optimizing the vaginal microbiome In African, Caribbean and other Black women from Toronto, Canada: defining clinical endpoints and community priorities
优化来自加拿大多伦多的非洲、加勒比和其他黑人女性的阴道微生物组:确定临床终点和社区优先事项
- 批准号:
494152 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Operating Grants
Promoting Inclusion in Clinical Trials: Understanding the participant-related barriers for new immigrants to Canada
促进临床试验的包容性:了解加拿大新移民与参与者相关的障碍
- 批准号:
485595 - 财政年份:2023
- 资助金额:
$ 1.1万 - 项目类别:
Miscellaneous Programs
Canadian Critical Care Trials Group COVID-19 Response: defining critical care capacity in Canada; testing treatments through large-scale adaptive clinical trials; & establishing the evidence base to inform clinical and health system management decisions
加拿大重症监护试验组 COVID-19 响应:定义加拿大的重症监护能力;
- 批准号:
466020 - 财政年份:2022
- 资助金额:
$ 1.1万 - 项目类别:
Directed Grant
Canadian Critical Care Trials Group COVID-19 Response: defining critical care capacity in Canada; testing treatments through large-scale adaptive clinical trials; & establishing the evidence base to inform clinical and health system management decisions
加拿大重症监护试验组 COVID-19 响应:定义加拿大的重症监护能力;
- 批准号:
465699 - 财政年份:2022
- 资助金额:
$ 1.1万 - 项目类别:
Directed Grant
Increasing capacity for Maternal and PAediatric Clinical Trials (IMPACT) in Canada
提高加拿大孕产妇和儿科临床试验 (IMPACT) 的能力
- 批准号:
466180 - 财政年份:2022
- 资助金额:
$ 1.1万 - 项目类别:
Operating Grants
Accelerating Clinical Trials (ACT) - Canada
加速临床试验 (ACT) - 加拿大
- 批准号:
471359 - 财政年份:2022
- 资助金额:
$ 1.1万 - 项目类别:
Operating Grants
Accelerating Clinical Trials (ACT) - Canada
加速临床试验 (ACT) - 加拿大
- 批准号:
467903 - 财政年份:2022
- 资助金额:
$ 1.1万 - 项目类别:
Operating Grants
Canada-Africa Monkeypox Partnership (CAMP): Characterizing transmission dynamics and evaluating medical countermeasures to inform the clinical and public health response to Mpox
加拿大-非洲猴痘合作伙伴关系 (CAMP):描述传播动态并评估医疗对策,为临床和公共卫生应对 Mpox 提供信息
- 批准号:
471053 - 财政年份:2022
- 资助金额:
$ 1.1万 - 项目类别:
Operating Grants